Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | GAA | P10253 | 5/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | GLA | P06280 | 2/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CFTR | P13569 | 3/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7896855 | 0.89 | KDM4E (0.52) | KDM4EALDH1A1GAAHSD17B10HPGD | |
| SCHEMBL8473587 | 0.87 | KDM4E (0.50) | KDM4EALDH1A1GAAHSD17B10HPGD | |
| SCHEMBL1567667 | 0.87 | KDM4E (0.59) | KDM4EALDH1A1GAAHSD17B10HPGD | |
| SCHEMBL18432612 | 0.86 | KMT2A (0.46) | KDM4EALDH1A1GAAHSD17B10HPGD | |
| SCHEMBL2811951 | 0.86 | KDM4E (0.53) | KDM4EALDH1A1GAAHSD17B10HPGD | |
| SCHEMBL30280995 | 0.85 | KDM4E (0.55) | KDM4EALDH1A1GAAHSD17B10HPGD | |
| SCHEMBL2318882 | 0.85 | KDM4E (0.55) | KDM4EALDH1A1GAAHSD17B10HPGD | |
| SCHEMBL2538919 | 0.85 | KMT2A (0.44) | KDM4EALDH1A1GAAHSD17B10HPGD | |
| SCHEMBL29906742 | 0.84 | GAA (0.50) | KDM4EALDH1A1GAAHSD17B10HPGD | |
| SCHEMBL15133527 | 0.83 | KDM4E (0.59) | KDM4EALDH1A1GAAHSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025056518-A1 | 5,6-DISUBSTITUTED ALKYL 1H AND 2H-INDAZOLES AS DUAL BUTYRYLCHOLINESTERASE AND p38α MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES | UNIVERZA V LJUBLJANI (SI) | 2025-03-20 | — | — | WO | disclosed |
| CN-115504986-B | Apoptosis signal regulating kinase inhibitor and preparation method and application thereof | 江苏豪森药业集团有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20240150355-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2024-05-09 | — | — | US | disclosed |
| CN-112236431-B | Purinone Compounds and Their Use in the Treatment of Cancer | 阿斯利康(瑞典)有限公司 | 2024-02-13 | — | — | CN | disclosed |
| US-11884671-B2 | Purinone compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2024-01-30 | — | — | US | disclosed |
| CN-111107848-B | Pharmaceutical composition containing amide derivatives, and preparation method and application thereof | 江苏豪森药业集团有限公司 | 2023-05-23 | — | — | CN | disclosed |
| CN-115504986-A | Apoptosis signal regulating kinase inhibitor and preparation method and application thereof | 江苏豪森药业集团有限公司 | 2022-12-23 | — | — | CN | disclosed |
| CN-111094250-B | Apoptosis signal regulating kinase inhibitor and preparation method and application thereof | 江苏豪森药业集团有限公司 | 2022-11-04 | — | — | CN | disclosed |
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
| EP-3807278-B1 | PURINONE DERIVATIVES AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2022-08-31 | — | — | EP | disclosed |
| US-20080242596-A1 | BENZYLIC GLYCOSIDE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2008-10-02 | — | — | US | disclosed |
| US-20080242596-A1 | BENZYLIC GLYCOSIDE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2008-10-02 | — | — | US | disclosed |
| WO-2007140191-A2 | GLUCOSE TRANSPORT INHIBITORS AND METHODS OF USE | THERACOS, INC. (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007140191-A2 | GLUCOSE TRANSPORT INHIBITORS AND METHODS OF USE | THERACOS, INC. (US) | 2007-12-06 | — | — | WO | disclosed |
| US-20070275907-A1 | GLUCOSE TRANSPORT INHIBITORS AND METHODS OF USE | SEED, BRIAN | 2007-11-29 | — | — | US | disclosed |
| US-20070275907-A1 | GLUCOSE TRANSPORT INHIBITORS AND METHODS OF USE | SEED, BRIAN | 2007-11-29 | — | — | US | disclosed |
| US-20070275907-A1 | GLUCOSE TRANSPORT INHIBITORS AND METHODS OF USE | SEED, BRIAN | 2007-11-29 | — | — | US | disclosed |
| EP-1389194-A2 | INHIBITORS OF BACE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-02-18 | — | — | EP | disclosed |
| US-20030095958-A1 | Inhibitors of bace | VERTEX PHARMACEUTICALS INCORPORATED | 2003-05-22 | — | — | US | disclosed |
| WO-2002088101-A2 | INHIBITORS OF BACE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030095958-A1 | Inhibitors of bace | BACE2, BACE1, APP | KDM4E 1717/4885ALDH1A1 2007/4885GAA 38/4885 |
| US-20240150355-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | RECQL, PRPS1, PURB | KDM4E 1890/4885ALDH1A1 185/4885GAA 1653/4885 |
| US-20070275907-A1 | GLUCOSE TRANSPORT INHIBITORS AND METHODS OF USE | SLC5A1, SLC5A2, SLC2A1 | KDM4E 2973/4885ALDH1A1 1010/4885GAA 223/4885 |
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KDM4E 190/4885ALDH1A1 2776/4885GAA 1234/4885 |
| US-11884671-B2 | Purinone compounds and their use in treating cancer | RECQL, PRPS1, PURB | KDM4E 2288/4885ALDH1A1 120/4885GAA 1550/4885 |
| US-20080242596-A1 | BENZYLIC GLYCOSIDE DERIVATIVES AND METHODS OF USE | SLC5A2, SLC5A1, SLC2A1 | KDM4E 2141/4885ALDH1A1 1224/4885GAA 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.